Tapan Maniar

1.7k total citations
17 papers, 246 citations indexed

About

Tapan Maniar is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine. According to data from OpenAlex, Tapan Maniar has authored 17 papers receiving a total of 246 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 6 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Tapan Maniar's work include Bone health and treatments (8 papers), CAR-T cell therapy research (7 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Tapan Maniar is often cited by papers focused on Bone health and treatments (8 papers), CAR-T cell therapy research (7 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Tapan Maniar collaborates with scholars based in United States, United Kingdom and Japan. Tapan Maniar's co-authors include Dirk Nagorsen, Zachary Zimmerman, Ada Braun, Miguel Martín, Jean-Jacques Body, Huei Wang, Yasuhiro Fujiwara, Janet E. Brown, Paul Sieber and Karim Fizazi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Tapan Maniar

17 papers receiving 242 citations

Peers

Countries citing papers authored by Tapan Maniar

Since Specialization

Citations

This map shows the geographic impact of Tapan Maniar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tapan Maniar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tapan Maniar more than expected).

Fields of papers citing papers by Tapan Maniar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tapan Maniar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tapan Maniar. The network helps show where Tapan Maniar may publish in the future.

Co-authorship network of co-authors of Tapan Maniar

This figure shows the co-authorship network connecting the top 25 collaborators of Tapan Maniar. A scholar is included among the top collaborators of Tapan Maniar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tapan Maniar. Tapan Maniar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Updated Results from a Phase I Dose Escalation Study of the Rapidly-Switchable Universal CAR-T Therapy UniCAR-T-CD123 in Relapsed/Refractory AML 2023 ·Blood ·Martin Wermke, Stephan Metzelder, Sabrina Kraus, Elisa Sala, Vladan Vučinić, Walter Fiedler, (unknown), Jonas Schäfer, Maria-Elisabeth Goebeler, Jan Koedam, Kristin Franke, (unknown), Armin Ehninger, Marc Cartellieri, Gerhard Ehninger, Tapan Maniar	21
2	Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer 2015 ·Supportive Care in Cancer ·Alison Stopeck, Karim Fizazi, Jean-Jacques Body, Janet E. Brown, Michael A. Carducci, Ingo Diel, Yasuhiro Fujiwara, Miguel Martín, Alexander Paterson, Katia Tonkin, Neal D. Shore, Paul Sieber, (unknown), Lawrence I. Karsh, Denise A. Yardley, Huei Wang, Tapan Maniar, Jorge Arellano, Ada Braun	136
3	Factors influencing outcomes in patients (Pts) with relapsed/refractory b-precursor acute lymphoblastic leukemia (r/r ALL) treated with blinatumomab in a phase 2 study. 2015 ·Journal of Clinical Oncology ·Hagop M. Kantarjian, Nicola Gökbuget, Susan O’Brien, Anthony S. Stein, Catherine Jia, Stephen J. Forman, Ralf C. Bargou, Adele K. Fielding, Leonard T. Heffner, Richard A. Larson, Svenja Neumann, Tapan Maniar, Dirk Nagorsen, Max S. Topp	2
4	An Evaluation of Molecular Response in a Phase 2 Open-Label, Multicenter Confirmatory Study in Patients (pts) with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Receiving Treatment with the BiTE® Antibody Construct Blinatumomab 2014 ·Blood ·Nicola Goekbuget, Hagop M. Kantarjian, Monika Brüggemann, Anthony S. Stein, Ralf C. Bargou, Hervé Dombret, Adele K. Fielding, Leonard T. Heffner, Françoise Rigal‐Huguet, Mark R. Litzow, Susan O’Brien, Gerhard Zugmaier, Catherine Jia, Tapan Maniar, Birgit Huber, Dirk Nagorsen, Stephen J. Forman, Max S. Topp	8
5	Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) 2014 ·Blood ·Anthony S. Stein, Max S. Topp, Nicola Goekbuget, Ralf C. Bargou, Hervé Dombret, Adele K. Fielding, Richard A. Larson, Alessandro Rambaldi, Gary J. Schiller, Gerhard Zugmaier, Catherine Jia, Tapan Maniar, Birgit Huber, Dirk Nagorsen, Hagop M. Kantarjian, Stephen J. Forman	5
6	Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy 2014 ·International Immunology ·Zachary Zimmerman, Tapan Maniar, Dirk Nagorsen	35
7	Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL). 2014 ·Journal of Clinical Oncology ·Max S. Topp, Nicola Goekbuget, Anthony S. Stein, Ralf C. Bargou, Hervé Dombret, Adele K. Fielding, Josep‐María Ribera, Robin Foà, Gerhard Zugmaier, Chris Holland, Tapan Maniar, Birgit Huber, Dirk Nagorsen, Hagop M. Kantarjian	14
8	Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial. 2013 ·Journal of Clinical Oncology ·Paul E. Goss, Carlos H. Barrios, Arlene Chan, Dianne M. Finkelstein, Hiroji Iwata, Miguel Martín, Ada Braun, Beiying Ding, Tapan Maniar, Robert E. Coleman	6
9	Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases. 2013 ·Journal of Clinical Oncology ·Luís Costa, Karim Fizazi, Fred Saad, Janet E. Brown, Roger von Moos, Stéphane Oudard, Cora N. Sternberg, Vinod Ganju, Kurt Miller, Huei Wang, Tapan Maniar, Ada Braun	2
10	Abstract OT2-6-02: Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): A global, placebo-controlled, randomized, double-blind, phase 3 clinical trial 2013 ·Cancer Research ·(unknown), (unknown), Anthony W.H. Chan, (unknown), (unknown), María P. Martín, Ada Braun, Yuhao Zhou, Tapan Maniar, RE Coleman	2
11	Denosumab Versus Placebo as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Disease Recurrence (D-CARE): An in Progress, Phase 3 Clinical Trial 2012 ·Annals of Oncology ·Robert E. Coleman, Carlos H. Barrios, R. Bell, Dianne M. Finkelstein, Hiroji Iwata, Miguel Martín, Ada Braun, Chunlei Ke, Tapan Maniar, (unknown)	2
12	Abstract OT2-3-03: Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase 3 clinical trial 2012 ·Cancer Research ·(unknown), (unknown), Anthony T.�C. Chan, (unknown), (unknown), María P. Martín, Ada Braun, Chunlei Ke, Tapan Maniar, RE Coleman	1
13	Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial. 2012 ·Journal of Clinical Oncology ·Paul E. Goss, Carlos H. Barrios, Richard H. Bell, Dianne M. Finkelstein, Hiroji Iwata, Miguel Martín, Ada Braun, Chunlei Ke, Tapan Maniar, Robert E. Coleman	2
14	OT1-01-03: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Comparing Denosumab with Placebo as Adjuvant Treatment for Women with Early-Stage Breast Cancer Who Are at High Risk of Disease Recurrence (D-CARE). 2011 ·Cancer Research ·(unknown), (unknown), R. Bell, David Finkelstein, (unknown), María P. Martín, Ada Braun, Chunlei Ke, Tapan Maniar, (unknown), Roger Dansey, RE Coleman	1
15	Phase II Trial of Lenalidomide - Dexamethasone - Rituximab in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab. 2009 ·Blood ·Tahamtan Ahmadi, Elise A. Chong, (unknown), Nicole A. Aqui, Lisa Downs, Leah I. Leinbach, Steven C. Goldstein, Sunita D. Nasta, (unknown), Tapan Maniar, Jakub Svoboda, Stephen J. Schuster	1
16	Chronic Lymphocytic Leukemia: New Concepts and Emerging Therapies 2009 ·Current Treatment Options in Oncology ·Tahamtan Ahmadi, Tapan Maniar, Stephen J. Schuster, Edward A. Stadtmauer	4
17	Childhood ALL and second neoplasms 2007 ·Cancer Biology & Therapy ·Tapan Maniar, Inbal Braunstein, Stephen J. O’Keefe, (unknown), (unknown), (unknown), Wafik S. El‐Deiry	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact